Overview
Cellectricon provides customized in vitro neurobiology research services to accelerate early drug discovery for pharmaceutical clients. Their offerings include target discovery, lead discovery, phenotypic screening, and neurotoxicity testing using complex models like primary neuronal cultures, iPSC-derived neurons, and tri-cultures of neurons, astrocytes, and microglia. Based in Sweden, they focus on areas such as peripheral neuropathies, neuroinflammation, neurodegeneration, and neuroplasticity, leveraging expertise in cell biology and advanced technologies.
Frequently asked questions
- What are Cellectricon's core capabilities in pharma drug discovery?
- Cellectricon specializes in target discovery, lead discovery, phenotypic and target-based assay development, screening, lead optimization, and neurotoxicity testing using physiologically relevant in vitro neurobiology models.
- What regulatory standards or quality practices does Cellectricon follow?
- Cellectricon adheres to pharmaceutical industry standards with robust best practices, ensuring high-quality primary cell cultures and assays for high-capacity applications, though specific regulatory certifications are not detailed.
- Where is Cellectricon located and what geographies do they serve?
- Cellectricon is based in Mölndal, Sweden, and serves global pharmaceutical and biotech clients, including partnerships with companies like Delix Therapeutics.